Nuvation Company Profile
What is the competitive landscape for NUVATION
NUVATION has one approved drug.
There are two US patents protecting NUVATION drugs.
Drugs and US Patents for Nuvation
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvation | IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713-001 | Jun 11, 2025 | RX | Yes | Yes | 9,751,887 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Nuvation | IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713-001 | Jun 11, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nuvation | IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713-001 | Jun 11, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nuvation | IBTROZI | taletrectinib adipate | CAPSULE;ORAL | 219713-001 | Jun 11, 2025 | RX | Yes | Yes | 9,187,489 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nuvation Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013183578 | ⤷ Start Trial |
| Japan | WO2013183578 | ⤷ Start Trial |
| Portugal | 2857404 | ⤷ Start Trial |
| Philippines | 12014502721 | ⤷ Start Trial |
| New Zealand | 702574 | ⤷ Start Trial |
| Israel | 236075 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |

